Clorox (CLX) Valuation Check After Recent Share Price Rebound And Ongoing ERP Transition Narrative

Why Clorox Stock Is on Investors’ Radar Today

Clorox (CLX) is drawing fresh attention after recent share price moves. The stock closed at US$92.00 as investors weigh its household, health and wellness, lifestyle, and international product exposure.

See our latest analysis for Clorox.

The recent 1-day share price return of 3.24% and 7-day share price return of 2.21% come after a tougher patch, with the 30-day share price return down 11.02% and the 90-day share price return down 26.19%. The 1-year total shareholder return is down 27.93%, suggesting that recent momentum is tentative against a weaker longer term record.

If you are reassessing your portfolio after Clorox's recent moves, this can be a good moment to broaden your search and check out 20 top founder-led companies

With Clorox trading at US$92.00 and an indicated intrinsic discount of about 46%, some investors may see value, while others might argue recent pressures are justified. This raises the question: is this a buying opportunity, or is future growth already priced in?

Most Popular Narrative: 20.3% Undervalued

Against the last close at $92.00, the most followed narrative implies a fair value of $115.47, using a 6.98% discount rate to evaluate future cash flows.

The full-scale implementation of a modern ERP system is expected to drive long-term operational efficiencies, improving supply chain visibility, speeding innovation cycles, and reducing structural costs. This is expected to support margin expansion and sustained earnings growth once short-term transition noise normalizes.

Read the complete narrative.

Want the full picture behind that valuation gap? The narrative leans heavily on steady revenue gains, firmer margins, and a future earnings multiple that assumes meaningful progress.

Result: Fair Value of $115.47 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, this hinges on Clorox holding its pricing power, while slower category growth or heavier discounting from rivals could pressure margins and weaken the ERP-driven margin story.

Find out about the key risks to this Clorox narrative.

Next Steps

Unsure what this means for Clorox? Act while the data is fresh and test the thesis for yourself by weighing its 4 key rewards and 2 important warning signs

Looking for more investment ideas?

You do not need to stop with Clorox. Give yourself options by scanning other stocks that fit clear, sensible criteria before the next move catches you off guard.

• Pinpoint stocks that combine quality with potential value by running your filters through 46 high quality undervalued stocks
• Zero in on companies that prioritize resilience and lower risk using the 68 resilient stocks with low risk scores
• Uncover lesser known opportunities with solid fundamentals by checking the screener containing 23 high quality undiscovered gems

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com